Search clinical trials for: JNJ 56021927

Total 1088 results

Janssen Pharmaceutical K.K.

Completed

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

Healthy

Japan
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
Aragon Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

Healthy

United States
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutical K.K.

Completed

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Japan
Aragon Pharmaceuticals, Inc.

No longer available

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Colombia, Brazil, Mexico
Janssen Research & Development, LLC

Active, not recruiting

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIB Prostate Cancer AJCC v8

United States
University of Washington
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Terminated

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
CCTU- Cancer Theme
Janssen-Cilag Ltd.

Completed

Therapeutics in Active Prostate Cancer Surveillance (TAPS01)

Prostate Cancer

United Kingdom
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (YATAGARASU)

Salivary Gland Neoplasms

Japan
National Cancer Institute (NCI)

Not yet recruiting

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

Prostatic Neoplasms

Italy, Russian Federation, Brazil, Portugal, Belgium, Spain, United States, Austria, Hungary, Turkey, Germany, Australia, Poland, Mexico, Finland, Slovakia, Lebanon, Czechia, Denmark, Jordan, Sweden
University of California, San Francisco
Janssen Pharmaceuticals

Active, not recruiting

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer (PILLAR)

Castration-Resistant Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER (BALANCE)

PSA Progression | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States, Canada
Janssen Research & Development, LLC

Completed

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostatic Neoplasms

Canada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
Horng Chen
FlowMedica, Inc.

Terminated

Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure

Cardiorenal Syndrome

United States
Janssen Research & Development, LLC

Completed

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Prostatic Neoplasms

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN)

Prostate Cancer

United States, France, Poland, Ukraine, United Kingdom, China, Spain, Argentina, Israel, Mexico, Romania, Turkey, Korea, Republic of, Japan, Sweden, Canada, Russian Federation, Brazil, Germany, Hungary, Czechia, Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Prostatic Neoplasms

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditions

United States
The University of Texas Health Science Center,...
Janssen Scientific Affairs, LLC

Withdrawn

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
University of Michigan; Weill Medical College of Cornell University; Janssen...

Active, not recruiting

AASUR in High Risk Prostate Cancer

Prostate Cancer

United States
Sanofi

Completed

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (PHOENIX)

Major Depressive Disorder

United States, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

Prostatic Neoplasms

United States, Italy, Czechia, Israel, Japan, Taiwan, Korea, Republic of, United Kingdom, France, Spain, Germany, Australia, Canada, Brazil, Netherlands, Russian Federation, Argentina, Poland
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Lymphoma, Non-Hodgkin

Denmark, Israel, Spain, Australia
Janssen-Cilag International NV

Completed

A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants

Healthy
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Israel, Korea, Republic of, Netherlands, Belgium, Spain, Australia, Poland, France, Georgia, Moldova, Republic of, Ukraine
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Healthy

Belgium
Johnson & Johnson Enterprise Innovation Inc.

Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Advanced Solid Tumors

United States
Janssen Cilag N.V./S.A.

Completed

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

Healthy

Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers

Health

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

Healthy

United States
Janssen R&D Ireland

Completed

A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants

Healthy Participants

Belgium
Janssen Research & Development, LLC

Terminated

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden

3

Subscribe